PMV Pharmaceuticals Appoints Matt Eckler to Board; Plans Q1 2027 NDA for Rezatapopt

PMV Pharmaceuticals, Inc.

Dr. Matthew Eckler was appointed to PMV Pharmaceuticals' board on October 1, 2026, with a term expiring at the 2029 annual meeting.
Eckler is a Principal at Samsara BioCapital and previously worked at ArrowMark Partners and GMT Capital; he will receive $40,000 annual cash compensation.
He received an initial stock option award for 84,000 shares and is expected to receive annual options for 42,000 shares under the outside director policy.
PMV plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation in Q1 2027.
The PYNNACLE Phase 2 monotherapy portion completed enrollment; rezatapopt has FDA Fast Track and Orphan Drug designations.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.